Ornidazole information

Ornidazole
Clinical data
Trade names	Xynor
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	G01AF06 (WHO) J01XD03 (WHO) P01AB03 (WHO) QP51AA03 (WHO);
Pharmacokinetic data
Metabolism	Via liver
Elimination half-life	12-13 hours
Excretion	Urine (63%) and Feces (22%)
Identifiers
	IUPAC name 1-Chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol;
CAS Number	16773-42-5 ;
PubChem CID	28061;
ChemSpider	26102 ;
UNII	62XCK0G93T;
KEGG	D05274 ;
ChEBI	CHEBI:75176 ;
ChEMBL	ChEMBL1449676 ;
CompTox Dashboard (EPA)	DTXSID4045420 ;
ECHA InfoCard	100.037.099
Chemical and physical data
Formula	C7H10ClN3O3
Molar mass	219.63 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-] [N+](=O)c1cnc(n1CC(O)CCl)C;
	InChI InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3 ; Key:IPWKIXLWTCNBKN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ornidazole is an antibiotic used to treat protozoan infections.^[1]^: 1368 A synthetic nitroimidazole, it is commercially obtained from an acid-catalyzed reaction between 2-methyl-5-nitroimidazole and epichlorohydrin.^[2]

Antimicrobial spectrum is similar to that of metronidazole and is more well tolerated;^[1]^: 1368 however there are concerns of lower relative efficacy.^[3]

It was first introduced for treating trichomoniasis before being recognized for its broad anti-protozoan and anti-anaerobic-bacterial capacities.^[4]^: 1261 has also been investigated for use in Crohn's disease after bowel resection.^[5]

^ ^a ^b ^c ^d Kuhlmann FM, Fleckenstein JM (2017-01-01). "157 - Antiparasitic Agents". In Cohen J, Powderly WG, Opal SM (eds.). Infectious Diseases (Fourth ed.). Elsevier. pp. 1345–1372.e2. doi:10.1016/B978-0-7020-6285-8.00157-X. ISBN 978-0-7020-6285-8.
^ Sharma S, Anand N (January 1997). "Chapter 17 - Nitroheterocycles". In Sharma S, Anand N (eds.). Pharmacochemistry Library. Approaches to Design and Synthesis of Antiparasitic Drugs. Vol. 25. Elsevier. p. 428. doi:10.1016/S0165-7208(97)80039-6. ISBN 9780444894762.
^ Nagel JL, Aronoff DM (January 2015). "28 - Metronidazole". In Bennett JE, Dolin R, Blaser MJ (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth ed.). Content Repository Only!. p. 356. ISBN 978-1-4557-4801-3.
^ Wilcox MH (January 2017), "147 - Nitroimidazoles, Metronidazole, Ornidazole and Tinidazole; and Fidaxomicin", in Cohen J, Powderly WG, Opal SM (eds.), Infectious Diseases (Fourth ed.), Elsevier, pp. 1261–1263.e1, ISBN 978-0-7020-6285-8
^ Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. (April 2005). "Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial". Gastroenterology. 128 (4): 856–861. doi:10.1053/j.gastro.2005.01.010. PMID 15825069.

[:0-1] Kuhlmann FM, Fleckenstein JM (2017-01-01). "157 - Antiparasitic Agents". In Cohen J, Powderly WG, Opal SM (eds.). Infectious Diseases (Fourth ed.). Elsevier. pp. 1345–1372.e2. doi:10.1016/B978-0-7020-6285-8.00157-X. ISBN 978-0-7020-6285-8.

[2] Sharma S, Anand N (January 1997). "Chapter 17 - Nitroheterocycles". In Sharma S, Anand N (eds.). Pharmacochemistry Library. Approaches to Design and Synthesis of Antiparasitic Drugs. Vol. 25. Elsevier. p. 428. doi:10.1016/S0165-7208(97)80039-6. ISBN 9780444894762.

[3] Nagel JL, Aronoff DM (January 2015). "28 - Metronidazole". In Bennett JE, Dolin R, Blaser MJ (eds.). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth ed.). Content Repository Only!. p. 356. ISBN 978-1-4557-4801-3.

[4] Wilcox MH (January 2017), "147 - Nitroimidazoles, Metronidazole, Ornidazole and Tinidazole; and Fidaxomicin", in Cohen J, Powderly WG, Opal SM (eds.), Infectious Diseases (Fourth ed.), Elsevier, pp. 1261–1263.e1, ISBN 978-0-7020-6285-8

[pmid15825069-5] Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. (April 2005). "Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial". Gastroenterology. 128 (4): 856–861. doi:10.1053/j.gastro.2005.01.010. PMID 15825069.

Ornidazole information

and 20 Related for: Ornidazole information

Ornidazole

ATC code J01

Nitroimidazole

Antiprotozoal

Amebicide

List of infectious diseases

Dientamoeba fragilis

Schedule H

Giardiasis

Ofloxacin

Prontosil

ATC code G01

Protozoan infection

ATC code P01

Entamoeba polecki

Antitrichomonal agent

Dextran drug delivery systems

ATCvet code QP51

Dehydroemetine

Hachimycin

Clinical data

Trade names	Xynor
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	G01AF06 (WHO) J01XD03 (WHO) P01AB03 (WHO) QP51AA03 (WHO)
Pharmacokinetic data
Metabolism	Via liver^[1]^: 1356
Elimination half-life	12-13 hours^[1]^: 1356
Excretion	Urine (63%) and Feces (22%)
Identifiers
IUPAC name 1-Chloro-3-(2-methyl-5-nitro-1H-imidazol-1-yl)propan-2-ol
CAS Number	16773-42-5^Y
PubChem CID	28061
ChemSpider	26102^Y
UNII	62XCK0G93T
KEGG	D05274^Y
ChEBI	CHEBI:75176^N
ChEMBL	ChEMBL1449676^N
CompTox Dashboard (EPA)	DTXSID4045420
ECHA InfoCard	100.037.099
Chemical and physical data
Formula	C₇H₁₀ClN₃O₃
Molar mass	219.63 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES [O-] [N+](=O)c1cnc(n1CC(O)CCl)C
InChI InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3^Y Key:IPWKIXLWTCNBKN-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)